New microspheres target the gut and blood vessels to treat disease

Engineered microspheres deliver probiotics and inhibitors to fix a cycle of inflammation in the gut and vascular system.

Scientists built engineered synbiotic microspheres to treat chronic inflammatory vascular disease. These microspheres target the gut-immune-vascular axis. This axis is a system-level pathogenic unit.

The axis connects gut microbial dysbiosis, intestinal barrier dysfunction, metabolic imbalance, and vascular immune activation. Dysbiosis is a disruption in the gut microbes. The intestinal barrier is a layer that can suffer from dysfunction. Vascular immune activation involves the immune system in the blood vessels.

The microspheres use a protective polymeric matrix. They deliver probiotics, a prebiotic, and a microbial metabolic pathway inhibitor. These spheres activate specifically in the intestine using enzymes.

This system restores the intestinal barrier and reprograms microbial ecology. It suppresses immunometabolic dysfunction and reduces pathological vascular remodeling. Testing occurred in cellular, murine, and large-animal models.

The work uses in-stent restenosis as a representative disease context. This approach establishes axis-oriented immunometabolic reprogramming as a generalizable therapeutic paradigm. It shows these platforms are scalable tools for system-level intervention.

Key facts

  • The microspheres deliver probiotics, a prebiotic, and a microbial metabolic pathway inhibitor.
  • The treatment works across cellular, murine, and large-animal models.
  • The system targets the gut-immune-vascular axis to address chronic inflammatory vascular disease.

All sections

Edition